Format

Send to

Choose Destination
Pharmacol Rep. 2011;63(3):629-42.

Treatment of inflammatory bowel disease (IBD).

Author information

1
Department of Pharmacology, L.M. College of Pharmacy, Navrangpura, Ahmedabad-3800 09 Gujarat, India. abpithadia@hotmail.com

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disease of the gastrointestinal tract, which includes Crohn's disease (CD) and ulcerative colitis (UC). These diseases have become important health problems. Medical therapy for IBD has advanced dramatically in the last decade with the introduction of targeted biologic therapies, the optimization of older therapies, including rugs such as immunomodulators and 5-aminosalicylic acid (5-ASA), and a better understanding of the mucosal immune system and the genetics involved in the pathogenesis of IBD. The goal of IBD therapy is to induce and maintain remission. The current treatment paradigm involves a step-up approach, moving to aggressive, powerful therapies only when milder therapies with fewer potential side effects fail or when patients declare themselves to have an aggressive disease. This review focuses on the current treatments for inflammatory bowel disease.

PMID:
21857074
DOI:
10.1016/s1734-1140(11)70575-8
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Institute of Pharmacology Polish Academy of Sciences
Loading ...
Support Center